Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients
- 1 August 1996
- journal article
- Published by Elsevier BV in Kidney International
- Vol. 50 (2), 543-549
- https://doi.org/10.1038/ki.1996.347
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- T cell activation defect in hemodialysis patients: Evidence for a role of the B7/CD28 pathwayKidney International, 1993
- Uremic serum effects on peripheral blood mononuclear cell and purified T lymphocyte responsesKidney International, 1992
- The Use of Vaccines in Renal FailureClinical Pharmacokinetics, 1992
- Stimulating erythropoiesis increases complement receptor expression on primate erythrocytesClinical Immunology and Immunopathology, 1992
- Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patientsKidney International, 1991
- Erythropoietin enhances immunoglobulin production and proliferation by human plasma cells in a serum-free mediumClinical Immunology and Immunopathology, 1991
- Effect of Converting Enzyme Inhibitor Captopril on T Cell Functions in Essential HypertensionNephron, 1991
- Effect of recombinant human erythropoietin on human IgE production in vitroClinical and Experimental Immunology, 1991
- Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunityKidney International, 1990
- Recombinant human erythropoietin activates a broad spectrum of progenitor cellsKidney International, 1990